# Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

> **NCT03110380** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 567 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** B/F/TAF
- **DRUG:** F/TAF
- **DRUG:** DTG
- **DRUG:** DTG Placebo
- **DRUG:** F/TAF Placebo
- **DRUG:** B/F/TAF Placebo

## Key facts

- **NCT ID:** NCT03110380
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-12-04
- **Final completion:** 2021-02-10
- **Target enrollment:** 567 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110380, "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03110380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*